S&P 500 Rally Continues

This is a Kresladi news story, published by Yahoo Finance, that relates primarily to Strong Buys news.

Kresladi news

For more Kresladi news, you can click here:

more Kresladi news

Strong Buys news

For more Strong Buys news, you can click here:

more Strong Buys news

mental health treatments news

For more mental health treatments news, you can click here:

more mental health treatments news

Yahoo Finance news

For more news from Yahoo Finance, you can click here:

more news from Yahoo Finance

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about

next hot stock

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Best Stocks news, investor sentiment news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

upside stocks

TipRanks

•

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

Summary

Nutrition label

80% Informative

Analysts at Morgan Stanley have highlighted two stocks they believe are poised for significant gains in the coming year with potential upside as high as 220% in one case.

Both stocks are also rated as Strong Buys by the analyst consensus.

The S&P 500 has rallied nearly 9% since its August 5th low.

One effective strategy is to focus on high-upside stocks endorsed by top-tier investment banks like Morgan Stanley .

Rocket’s most advanced programs focus on hematology.

The company is advancing LV RP-L102 , a drug candidate designed to treat Fanconi anemia and Kresladi , a potential treatment for LAD-1 .

Morgan Stanley analyst Michael Ulz is particularly impressed by the cardiovascular advancements.

Ulz complements his Overweight (i.e. Buy ) rating on RCKT with a $ 45 price target, implying a 142% gain for the stock in the coming 12 months .

VR Score

Informative language

Neutral language

Article tone

formal